Key Performance Indicators 2011
Unitaid strategy 2010-2012
Key Performance Indicators 2010
Unitaid audited financial report for period 2008-2009
Key Performance Indicators 2009
Unitaid’s climate and health strategy 2023-2027
Unitaid’s investment case 2023-2027, executive summary
Unitaid’s investment case 2023-2027
Unitaid Strategy 2023-2027
Maternal and newborn health
Women’s and children’s health
Global malaria diagnostic and artemisinin treatment commodities demand forecast: 2017 – 2021 Report (May 2018)
Fever Diagnostic Technology Landscape
Multi-disease diagnostics landscape for integrated management of HIV, HCV, TB and other coinfections
Hepatitis C medicines technology and market landscape
Unitaid’s approach to intellectual property
Discussion Paper: Ensuring that essential medicines are also affordable medicines: challenges and options
Discussion Paper: An economic perspective on delinking the cost of R&D from the price of medicines
Unitaid and the Government of Spain
About Unitaid (Saving lives faster)
Unitaid and the UK Government
Unitaid audited financial report for the year ended 31 December 2023
Partnership report: Unitaid and the Global Fund to Fight AIDS, Tuberculosis and Malaria
Unitaid audited financial report for the year ended 31 December 2022
Patent landscape: grazoprevir
Patent landscape: elbasvir
Patents and licenses on antiretrovirals: a snapshot
Malaria medicines technology and market landscape – 2nd edition
Malaria diagnostics market landscape – semi-annual update
Hepatitis C medicines technology and market landscape
Hepatitis C diagnostics technology landscape – 1st edition
HIV/AIDS diagnostics technology landscape – semi-annual update
